Search research articles
Contact Us
Filters
Showing results (11-20 of 27) with videos related to
Page
of 3
Sort By:
European Urology
|
June 4, 2023
A U.S. Food and Drug Administration-pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma
Daniel Lee, Haley Gittleman, Chana Weinstock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 17, 2024
Equipoise Lost? Trial Conduct Challenges in an Era of Breakthrough Therapies
Jaleh Fallah, Flora Mulkey, Mallorie H Fiero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2024
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma
William F Maguire, Daniel Lee, Chana Weinstock, et al.
The Oncologist
|
December 14, 2018
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy
Daniel L Suzman, Sundeep Agrawal, Yang-Min Ning, et al.
JCO Precision Oncology
|
August 29, 2024
False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring <i>ATM</i> and <i>CHEK2</i> Mutations
Jaleh Fallah, Jianjin Xu, Hee-Koung Joeng, et al.
JNCI Cancer Spectrum
|
July 16, 2025
The Food and Drug Administration pooled analysis of overall survival according to depth of response in frontline advanced immune-oncology renal cell carcinoma trials
Elaine Chang, Haley Gittleman, Chi Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 1, 2020
FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs
Paul G Kluetz, Patricia Keegan, George D Demetri, et al.
JAMA Oncology
|
December 29, 2022
Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021
Sundeep Agrawal, Shaily Arora, Laleh Amiri-Kordestani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 28, 2024
A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma
Elaine Chang, Jiaxi Zhou, Chi Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 5, 2022
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer
Jaleh Fallah, Sundeep Agrawal, Haley Gittleman, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 27) with videos related to
Sort By:
Page
of 3
European Urology
|
June 4, 2023
A U.S. Food and Drug Administration-pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma
Daniel Lee, Haley Gittleman, Chana Weinstock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 17, 2024
Equipoise Lost? Trial Conduct Challenges in an Era of Breakthrough Therapies
Jaleh Fallah, Flora Mulkey, Mallorie H Fiero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2024
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma
William F Maguire, Daniel Lee, Chana Weinstock, et al.
The Oncologist
|
December 14, 2018
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy
Daniel L Suzman, Sundeep Agrawal, Yang-Min Ning, et al.
JCO Precision Oncology
|
August 29, 2024
False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring <i>ATM</i> and <i>CHEK2</i> Mutations
Jaleh Fallah, Jianjin Xu, Hee-Koung Joeng, et al.
JNCI Cancer Spectrum
|
July 16, 2025
The Food and Drug Administration pooled analysis of overall survival according to depth of response in frontline advanced immune-oncology renal cell carcinoma trials
Elaine Chang, Haley Gittleman, Chi Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 1, 2020
FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs
Paul G Kluetz, Patricia Keegan, George D Demetri, et al.
JAMA Oncology
|
December 29, 2022
Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021
Sundeep Agrawal, Shaily Arora, Laleh Amiri-Kordestani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 28, 2024
A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma
Elaine Chang, Jiaxi Zhou, Chi Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 5, 2022
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer
Jaleh Fallah, Sundeep Agrawal, Haley Gittleman, et al.
Page
of 3